Home › Melanoma › Tennessee › Chattanooga
Melanoma clinical trials in Chattanooga, TN
4 studies for Melanoma are looking for participants at sites in and around Chattanooga (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RecruitingPhase 3
- Tennessee Oncology - Chattanooga, Chattanooga
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- Erlanger Health, Inc, Chattanooga
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- T C Thompson Children's Hospital, Chattanooga
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Tennessee Oncology, Chattanooga
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX61 studies
- New York City, NY41 studies
- Nashville, TN34 studies
- Los Angeles, CA34 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- St. Louis, MO23 studies
- Durham, NC22 studies
- Philadelphia, PA22 studies
- Tampa, FL21 studies
- Columbus, OH21 studies
- Dallas, TX21 studies
Other studies in Chattanooga
- Non-Small Cell Lung Cancer9 studies
- Myasthenia Gravis5 studies
- Metastatic Cancer5 studies
- Steatotic Liver Disease4 studies
- COPD4 studies
- Ischemic Stroke4 studies
- Ovarian Cancer4 studies
- Lung Cancer4 studies
- Stroke3 studies
- Diabetes3 studies
- Colorectal Cancer3 studies
- High Blood Pressure3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.